Developer docs
API playgroundTry for free, no card

Search company profiles

Qritive

Full company profile

uuid00028uc

Namestring
Qritive
Legal namestring
Qritive Pte. Ltd.
Websiteurl
qritive.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Qritive Pte. Ltd. is a Singapore-incorporated healthcare AI company founded in 2017 that develops deep learning-powered digital pathology solutions for cancer diagnosis. Its flagship platform, Pantheon™, is an AI-powered image management workbench that digitizes and streamlines the end-to-end pathology workflow, from whole-slide image viewing and case management to AI-assisted diagnosis and structured reporting. Qritive's AI module portfolio includes QAi Prostate Grade (prostate cancer grading aligned to ISUP Grade Group classifications), QAi Lymph Node Dx (segmentation-based detection of micro- and macrometastases across breast, colon, and gastric tumors), AI-Assisted Ki-67 Scoring (biomarker analysis for sarcoma), and biomarker analysis modules. The underlying technology combines region-based convolutional networks (Faster R-CNN with ResNet-50/101 backbone) for glandular segmentation with classical machine learning classifiers for composite diagnostic decisions, trained on a corpus of 400,000+ pathology images.

The company operates a B2B enterprise subscription model, monetizing AI diagnostic software modules, Pantheon platform licensing, and related Software-as-a-Medical-Device (SaMD) services through annual contracts to hospitals, pathology laboratories, and diagnostic chain networks. Pricing is quote-based and tailored to institutional scale, deployment requirements, and regulatory certifications, with annual billing. Go-to-market is primarily direct enterprise field sales targeting pathologists and laboratory decision-makers, supplemented by active presence at major pathology conferences (USCAP, ECDP, Medlab Middle East), peer-reviewed scientific publications, strategic partnerships with Roche, M42, Sectra, and Tribun Health, and participation in accelerator programs (MedTech Innovator Asia Pacific 2024, Cedars-Sinai Accelerator). The company holds CE marking, Singapore HSA Class C IVD registration, Abu Dhabi Department of Health approval, ISO 13485:2016, and ISO/IEC 27001:2022 certifications, and operates across Singapore, India, the United States, the UAE, Japan, and Europe with an 11-50 person team led by CEO and co-founder Aneesh Sathe and CTO and co-founder Kaveh Taghipour.

Qritive has raised approximately $9 million in disclosed funding, most recently a $7.5 million Series A in January 2023 led by MassMutual Ventures with SEEDS Capital and Exfinity Venture Partners. Named enterprise customers include Dr Lal PathLabs, Metropolis Healthcare, Rajiv Gandhi Cancer Institute and Research Centre, Cleveland Clinic Abu Dhabi, and M42's National Reference Laboratory. The company maintains a branded education platform, Qritive Academy, and pursues open-ecosystem integration through Sectra Amplifier Marketplace and Tribun Health's CaloPix Connect API alongside technology partnerships with Philips, AWS, NVIDIA, Dell, NTT, Corista, and Motic.

Short descriptiontext

Qritive is a Singapore-based AI healthcare company that builds deep learning-powered digital pathology software for cancer diagnosis. Its Pantheon platform and QAi modules help hospitals, pathology laboratories, and diagnostic chains automate detection, grading, and reporting for prostate, colon, and lymph node cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, AI cancer diagnostics, pathology image analysis, medical imaging AI, clinical decision support
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • Software Publishers51321
  • Software Publishers5132
SIC code2 codes
  • Services-Prepackaged Software7372
  • Laboratory Analytical Instruments3826
Product category
Digital Pathology Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI Diagnostic Software Modules
TypeSubscription Recurring
Description

Revenue from AI-powered diagnostic algorithms and modules deployed to healthcare institutions. Modules include QAi Prostate Grade, QAi Lymph Node Dx, and other cancer detection solutions sold to pathology labs and hospitals.

qritive.com
2Pantheon Platform Licensing
TypeSubscription Recurring
Description

Licensing of Pantheon image management system to pathology laboratories and healthcare institutions for digital pathology workflow management.

qritive.com
3Enterprise Software Services
TypeSubscription Recurring
Description

Services related to AI-based pathology diagnostic solutions developed as Software as a Medical Device (SaMD), including implementation and support.

qritive.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise licensing model for healthcare institutions
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing; specific tiers and price points not publicly disclosed

qritive.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Pantheon™
Description

AI-powered pathology workbench and image management platform for digitizing and streamlining the entire pathology workflow, from slide viewing and case management to AI-supported diagnosis and structured reporting. CE-marked and HSA-registered.

qritive.com
+3 more records
Core offering1 text field

Qritive develops and sells AI-powered digital pathology software — primarily the Pantheon™ image management platform and a suite of AI diagnostic modules (QAi Prostate Grade, QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, biomarker analysis) — to hospitals, pathology laboratories, and diagnostic chains for faster and more accurate cancer diagnosis. The platform and modules are sold as Software as a Medical Device (SaMD) under annual enterprise subscriptions with regulatory clearances including CE marking, Singapore HSA Class C IVD, and Abu Dhabi Department of Health approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Achieved AUC of 0.917 with 97.4% sensitivity for colorectal cancer detection
+2 more records
Product overview1 text field

Qritive offers an AI-powered digital pathology ecosystem centered on Pantheon™, an image management platform that digitizes and streamlines the entire pathology workflow. The portfolio includes AI diagnostic modules — QAi Prostate (including QAi Prostate Grade), QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, and other cancer diagnostic modules — all hardware-agnostic and designed to integrate with Pantheon™ or other image management systems. Qritive Academy provides supplementary pathology education. The platform is CE-marked, HSA-registered, and available globally through partnerships including Roche, M42, and Dr Lal PathLabs.

Product and service5 records
1Pantheon™ Image Management System
CategoryDigital Pathology Platform
Description

AI-powered pathology workbench and image management platform that digitizes and streamlines the entire pathology workflow — from slide viewing, case management, AI-supported diagnosis to structured reporting. Vendor-agnostic, cloud-ready, supports all major whole-slide image formats, and integrates with hospital systems, LIS, and external AI modules. CE-marked and HSA-registered.

2QAi Prostate (QAi Prostate Grade)
CategoryAI Cancer Diagnostic Module
Description

AI-powered diagnostic module that supports pathologists in achieving faster, more accurate prostate cancer diagnoses with greater confidence in reporting, including Gleason grading support. The QAi Prostate Grade module has received Class C IVD approval from Singapore HSA and regulatory approval from Abu Dhabi's Department of Health.

3QAi Lymph Node Dx
CategoryAI Cancer Diagnostic Module
Description

AI-powered module for detecting lymph node metastasis across multiple cancer types including breast, colon, and gastric tumors. Uses a segmentation-based deep learning approach to detect both micro- and macrometastases. Deployed at Dr Lal PathLabs in clinical workflows.

4AI-Assisted Ki-67 Scoring
CategoryAI Biomarker Analysis Module
Description

Computer vision-based AI module for evaluating Ki-67 proliferative index on IHC-stained whole-slide images, applied to sarcoma cases to reduce inter-observer variability and improve diagnostic reproducibility.

5Qritive Academy
CategoryPathology Education Platform
Description

Dedicated online platform for continuous learning and professional development in pathology, offering both foundational and advanced content tailored to diagnostic needs to make high-quality education accessible to pathologists worldwide.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

M42's National Reference Laboratory introduced AI-powered prostate cancer diagnostics in the UAE through partnership with Qritive, integrated into Cleveland Clinic Abu Dhabi's diagnostic workflow. Partnership supports UAE's healthcare innovation goals under Vision 2031.

Strategic tierCoreTypeTechnology or Integration
Description

Qritive's AI solutions available through Tribun Health's CaloPix Connect open API, enabling integration of third-party AI tools into digital pathology workflows. Qritive is listed among approved AI providers including Aiforia, DeepPath, Primaa, Owkin, and Ibex.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Strategic partnership announced September 2024 to redefine global cancer diagnostics with AI. Qritive featured as partner in Roche's digital pathology ecosystem.

Strategic tierCoreTypeTechnology or Integration
Description

Featured at Sectra Amplifier Marketplace, enabling integration of Qritive's AI solutions with Sectra's enterprise imaging platform for digital pathology.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Dr. Lal PathLabs selected Qritive's QAi Lymph Node Dx to enhance capabilities in detecting lymph node metastasis as part of routine clinical workflows. Collaborative study presented at USCAP 2025.

6Rajiv Gandhi Cancer Institute and Research Centre
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Clinical collaboration deploying QAi Prostate Grade module at RGCIRC in India, supported by MeitY-nasscom Center of Excellence. Real-world impact study demonstrating AI enhancement of prostate cancer diagnosis.

qritive.com
7Nagasaki University Graduate School of Biomedical Sciences
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaborative study with Dr. Kris Lami evaluating deep learning AI algorithm for detecting lymph node metastasis across multiple cancer types, presented at ECDP 2025.

qritive.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PathAI develops AI-powered pathology tools for cancer diagnosis and biomarker analysis, directly competing with Qritive's QAi Prostate Grade and Lymph Node Dx modules in the same hospital and reference-lab customer segment.

TypeDirect peer
Description

Paige builds clinical-grade AI applications for pathology including prostate, breast, and other cancer detection, overlapping directly with Qritive's cancer-specific diagnostic modules and target pathologist buyer.

TypeDirect peer
Description

Ibex provides an AI platform for cancer diagnostics in pathology (Galen, Second Read), competing head-to-head with Qritive's QAi suite for the same pathology lab and hospital customers globally.

TypeDirect peer
Description

Aiforia offers deep learning AI solutions for image-based diagnostics including pathology, with comparable prostate and other tissue analysis modules; listed alongside Qritive on Tribun Health's CaloPix Connect AI marketplace.

TypeDirect peer
Description

Owkin applies AI to pathology and oncology, including digital pathology AI tools; co-listed with Qritive as an approved AI provider on Tribun Health's CaloPix Connect platform, making it a direct competitor in third-party pathology AI.

TypeDirect peer
Description

Proscia offers a digital pathology platform (Concentriq) with embedded AI for cancer diagnostics, overlapping with Qritive's Pantheon image management and AI module offering for enterprise pathology customers.

TypeEmerging player
Description

Primaa develops AI algorithms for dermatopathology and other pathology use cases, also co-listed on Tribun Health's CaloPix Connect marketplace alongside Qritive's modules.

TypeEmerging player
Description

DeepPath provides AI-based pathology image analysis, also featured on Tribun Health's CaloPix Connect as a comparable third-party AI pathology provider to Qritive.

TypeBroad incumbent
Description

Lunit is a Korean AI medtech company with pathology and radiology AI products (including Lunit SCOPE), operating more broadly across cancer diagnostics than Qritive but with overlapping clinical buyers and use cases.

TypeBroad incumbent
Description

Roche operates a large digital pathology platform (uPath/Roche Digital Pathology) and is simultaneously a Qritive strategic partner and a competitor offering native AI; comparable as a broad incumbent with overlapping enterprise pathology footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qritive

Digital Pathology Softwareqritive.com

Qritive is a Singapore-based AI healthcare company that builds deep learning-powered digital pathology software for cancer diagnosis. Its Pantheon platform and QAi modules help hospitals, pathology laboratories, and diagnostic chains automate detection, grading, and reporting for prostate, colon, and lymph node cancers.

What Qritive does

Qritive Pte. Ltd. is a Singapore-incorporated healthcare AI company founded in 2017 that develops deep learning-powered digital pathology solutions for cancer diagnosis. Its flagship platform, Pantheon™, is an AI-powered image management workbench that digitizes and streamlines the end-to-end pathology workflow, from whole-slide image viewing and case management to AI-assisted diagnosis and structured reporting. Qritive's AI module portfolio includes QAi Prostate Grade (prostate cancer grading aligned to ISUP Grade Group classifications), QAi Lymph Node Dx (segmentation-based detection of micro- and macrometastases across breast, colon, and gastric tumors), AI-Assisted Ki-67 Scoring (biomarker analysis for sarcoma), and biomarker analysis modules. The underlying technology combines region-based convolutional networks (Faster R-CNN with ResNet-50/101 backbone) for glandular segmentation with classical machine learning classifiers for composite diagnostic decisions, trained on a corpus of 400,000+ pathology images.

The company operates a B2B enterprise subscription model, monetizing AI diagnostic software modules, Pantheon platform licensing, and related Software-as-a-Medical-Device (SaMD) services through annual contracts to hospitals, pathology laboratories, and diagnostic chain networks. Pricing is quote-based and tailored to institutional scale, deployment requirements, and regulatory certifications, with annual billing. Go-to-market is primarily direct enterprise field sales targeting pathologists and laboratory decision-makers, supplemented by active presence at major pathology conferences (USCAP, ECDP, Medlab Middle East), peer-reviewed scientific publications, strategic partnerships with Roche, M42, Sectra, and Tribun Health, and participation in accelerator programs (MedTech Innovator Asia Pacific 2024, Cedars-Sinai Accelerator). The company holds CE marking, Singapore HSA Class C IVD registration, Abu Dhabi Department of Health approval, ISO 13485:2016, and ISO/IEC 27001:2022 certifications, and operates across Singapore, India, the United States, the UAE, Japan, and Europe with an 11-50 person team led by CEO and co-founder Aneesh Sathe and CTO and co-founder Kaveh Taghipour.

Qritive has raised approximately $9 million in disclosed funding, most recently a $7.5 million Series A in January 2023 led by MassMutual Ventures with SEEDS Capital and Exfinity Venture Partners. Named enterprise customers include Dr Lal PathLabs, Metropolis Healthcare, Rajiv Gandhi Cancer Institute and Research Centre, Cleveland Clinic Abu Dhabi, and M42's National Reference Laboratory. The company maintains a branded education platform, Qritive Academy, and pursues open-ecosystem integration through Sectra Amplifier Marketplace and Tribun Health's CaloPix Connect API alongside technology partnerships with Philips, AWS, NVIDIA, Dell, NTT, Corista, and Motic.

Qritive firmographics

Firmographics
Name
Qritive
Legal name
Qritive Pte. Ltd.
Website
https://qritive.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Qritive is a Singapore-based AI healthcare company that builds deep learning-powered digital pathology software for cancer diagnosis. Its Pantheon platform and QAi modules help hospitals, pathology laboratories, and diagnostic chains automate detection, grading, and reporting for prostate, colon, and lymph node cancers.
Ownership category
akta.pro rank

Qritive industry classification

Industry
Product category
Digital Pathology Software
NAICS
Software Publishers (51321), Software Publishers (5132)
SIC
Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Digital pathology software
  • AI cancer diagnostics
  • Pathology image analysis
  • Medical imaging AI
  • Clinical decision support

Where Qritive is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices4 records

Markets served

Qritive business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI Diagnostic Software Modules: Revenue from AI-powered diagnostic algorithms and modules deployed to healthcare institutions. Modules include QAi Prostate Grade, QAi Lymph Node Dx, and other cancer detection solutions sold to pathology labs and hospitals.
  2. Pantheon Platform Licensing: Licensing of Pantheon image management system to pathology laboratories and healthcare institutions for digital pathology workflow management.
  3. Enterprise Software Services: Services related to AI-based pathology diagnostic solutions developed as Software as a Medical Device (SaMD), including implementation and support.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise licensing model for healthcare institutions

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Qritive product offering

Product offering

Core offering

Qritive develops and sells AI-powered digital pathology software — primarily the Pantheon™ image management platform and a suite of AI diagnostic modules (QAi Prostate Grade, QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, biomarker analysis) — to hospitals, pathology laboratories, and diagnostic chains for faster and more accurate cancer diagnosis. The platform and modules are sold as Software as a Medical Device (SaMD) under annual enterprise subscriptions with regulatory clearances including CE marking, Singapore HSA Class C IVD, and Abu Dhabi Department of Health approval.

Product overview

Qritive offers an AI-powered digital pathology ecosystem centered on Pantheon™, an image management platform that digitizes and streamlines the entire pathology workflow. The portfolio includes AI diagnostic modules — QAi Prostate (including QAi Prostate Grade), QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, and other cancer diagnostic modules — all hardware-agnostic and designed to integrate with Pantheon™ or other image management systems. Qritive Academy provides supplementary pathology education. The platform is CE-marked, HSA-registered, and available globally through partnerships including Roche, M42, and Dr Lal PathLabs.

Differentiator

Problem solved

Functional benefit

Brands

  • Pantheon™: AI-powered pathology workbench and image management platform for digitizing and streamlining the entire pathology workflow, from slide viewing and case management to AI-supported diagnosis and structured reporting. CE-marked and HSA-registered.
  • QAi Prostate
  • QAi Suite
  • Qritive Academy

Products and services

  • Pantheon™ Image Management System AI-powered pathology workbench and image management platform that digitizes and streamlines the entire pathology workflow — from slide viewing, case management, AI-supported diagnosis to structured reporting. Vendor-agnostic, cloud-ready, supports all major whole-slide image formats, and integrates with hospital systems, LIS, and external AI modules. CE-marked and HSA-registered.
  • QAi Prostate (QAi Prostate Grade) AI-powered diagnostic module that supports pathologists in achieving faster, more accurate prostate cancer diagnoses with greater confidence in reporting, including Gleason grading support. The QAi Prostate Grade module has received Class C IVD approval from Singapore HSA and regulatory approval from Abu Dhabi's Department of Health.
  • QAi Lymph Node Dx AI-powered module for detecting lymph node metastasis across multiple cancer types including breast, colon, and gastric tumors. Uses a segmentation-based deep learning approach to detect both micro- and macrometastases. Deployed at Dr Lal PathLabs in clinical workflows.
  • AI-Assisted Ki-67 Scoring Computer vision-based AI module for evaluating Ki-67 proliferative index on IHC-stained whole-slide images, applied to sarcoma cases to reduce inter-observer variability and improve diagnostic reproducibility.
  • Qritive Academy Dedicated online platform for continuous learning and professional development in pathology, offering both foundational and advanced content tailored to diagnostic needs to make high-quality education accessible to pathologists worldwide.

Quantifiable outcome

  • Achieved AUC of 0.917 with 97.4% sensitivity for colorectal cancer detection
  • +2 more outcomes

Companies that use Qritive

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Qritive technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature6 records

Qritive partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered strategic and core.

  • M42's National Reference LaboratorystrategicStrategic or Co-development Partner · 9 June 2026M42's National Reference Laboratory introduced AI-powered prostate cancer diagnostics in the UAE through partnership with Qritive, integrated into Cleveland Clinic Abu Dhabi's diagnostic workflow. Partnership supports UAE's healthcare innovation goals under Vision 2031.
  • Tribun HealthcoreTechnology or IntegrationQritive's AI solutions available through Tribun Health's CaloPix Connect open API, enabling integration of third-party AI tools into digital pathology workflows. Qritive is listed among approved AI providers including Aiforia, DeepPath, Primaa, Owkin, and Ibex.
  • RochestrategicStrategic or Co-development PartnerStrategic partnership announced September 2024 to redefine global cancer diagnostics with AI. Qritive featured as partner in Roche's digital pathology ecosystem.
  • SectracoreTechnology or IntegrationFeatured at Sectra Amplifier Marketplace, enabling integration of Qritive's AI solutions with Sectra's enterprise imaging platform for digital pathology.
  • Dr. Lal PathLabsstrategicStrategic or Co-development PartnerDr. Lal PathLabs selected Qritive's QAi Lymph Node Dx to enhance capabilities in detecting lymph node metastasis as part of routine clinical workflows. Collaborative study presented at USCAP 2025.
  • Rajiv Gandhi Cancer Institute and Research CentrestrategicStrategic or Co-development PartnerClinical collaboration deploying QAi Prostate Grade module at RGCIRC in India, supported by MeitY-nasscom Center of Excellence. Real-world impact study demonstrating AI enhancement of prostate cancer diagnosis.
  • Nagasaki University Graduate School of Biomedical SciencesstrategicStrategic or Co-development PartnerCollaborative study with Dr. Kris Lami evaluating deep learning AI algorithm for detecting lymph node metastasis across multiple cancer types, presented at ECDP 2025.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Qritive competitors and assessment

Company assessment

Direct peers

  • PathAI: PathAI develops AI-powered pathology tools for cancer diagnosis and biomarker analysis, directly competing with Qritive's QAi Prostate Grade and Lymph Node Dx modules in the same hospital and reference-lab customer segment.
  • Paige.AI: Paige builds clinical-grade AI applications for pathology including prostate, breast, and other cancer detection, overlapping directly with Qritive's cancer-specific diagnostic modules and target pathologist buyer.
  • Ibex Medical Analytics: Ibex provides an AI platform for cancer diagnostics in pathology (Galen, Second Read), competing head-to-head with Qritive's QAi suite for the same pathology lab and hospital customers globally.
  • Aiforia: Aiforia offers deep learning AI solutions for image-based diagnostics including pathology, with comparable prostate and other tissue analysis modules; listed alongside Qritive on Tribun Health's CaloPix Connect AI marketplace.
  • Owkin: Owkin applies AI to pathology and oncology, including digital pathology AI tools; co-listed with Qritive as an approved AI provider on Tribun Health's CaloPix Connect platform, making it a direct competitor in third-party pathology AI.
  • Proscia: Proscia offers a digital pathology platform (Concentriq) with embedded AI for cancer diagnostics, overlapping with Qritive's Pantheon image management and AI module offering for enterprise pathology customers.

Emerging players

  • Primaa: Primaa develops AI algorithms for dermatopathology and other pathology use cases, also co-listed on Tribun Health's CaloPix Connect marketplace alongside Qritive's modules.
  • DeepPath: DeepPath provides AI-based pathology image analysis, also featured on Tribun Health's CaloPix Connect as a comparable third-party AI pathology provider to Qritive.

Broad incumbents

  • Lunit: Lunit is a Korean AI medtech company with pathology and radiology AI products (including Lunit SCOPE), operating more broadly across cancer diagnostics than Qritive but with overlapping clinical buyers and use cases.
  • Roche (Roche Digital Pathology): Roche operates a large digital pathology platform (uPath/Roche Digital Pathology) and is simultaneously a Qritive strategic partner and a competitor offering native AI; comparable as a broad incumbent with overlapping enterprise pathology footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Qritive social profiles

Digital presence

Qritive compliance and trust

Trust signal

Compliance8 records

Qritive financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qritive leadership team

Management profile

Number of profiles

Profiles4 records

Qritive funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qritive M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qritive

What does Qritive do?

Qritive develops and sells AI-powered digital pathology software — primarily the Pantheon™ image management platform and a suite of AI diagnostic modules (QAi Prostate Grade, QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, biomarker analysis) — to hospitals, pathology laboratories, and diagnostic chains for faster and more accurate cancer diagnosis. The platform and modules are sold as Software as a Medical Device (SaMD) under annual enterprise subscriptions with regulatory clearances including CE marking, Singapore HSA Class C IVD, and Abu Dhabi Department of Health approval.

Is Qritive a public or private company?

Qritive is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qritive founded?

Qritive was founded in 2017. It employs 11 to 50 people.

Where is Qritive based?

Qritive is headquartered in Singapore, Singapore, in the Asia region.

How does Qritive make money?

Three revenue lines are on record. AI Diagnostic Software Modules are the primary driver. The others are pantheon Platform Licensing and enterprise Software Services.

Who are Qritive's main competitors?

Direct peers on record are PathAI, Paige.AI, Ibex Medical Analytics, Aiforia, Owkin and Proscia. Emerging players are Primaa and DeepPath. Broad incumbents are Lunit and Roche (Roche Digital Pathology).

Does Qritive have an API?

No public API is recorded for Qritive.

What industry is Qritive in?

Qritive's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 51321 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital Watch ObservatoryUAE laboratory introduces AI-powered prostate cancer diagnosticsM42's National Reference Laboratory has introduced an AI-powered tool for prostate cancer diagnostics in the UAE in partnership with digital pathology company Qritive, to be integrated into Cleveland Clinic Abu Dhabi's diagnostic workflow. The platform analyses digital pathology slides to help detect prostate cancer, assess tumour patterns, and support grading according to internationally recognised standards. The initiative forms part of NRL's strategy to strengthen oncology services and supports the UAE's broader objectives of advancing healthcare innovation under UAE Vision 2031.GulfNewsM42 Introduces AI-Powered Prostate Cancer Diagnostics in the UAE with Qritive PartnershipM42's National Reference Laboratory has launched an AI-powered prostate cancer diagnostics tool in the UAE through a partnership with digital pathology company Qritive. The technology, integrated at Cleveland Clinic Abu Dhabi, analyses digital pathology slides to help pathologists detect cancer and assess tumour severity more efficiently. The initiative supports the UAE's healthcare innovation goals under Vision 2031 and addresses growing demand for faster cancer diagnostics in the region, with an estimated 50,000 new prostate cancer cases diagnosed annually in the Middle East.TribunCaloPix Connect: An Open API to Integrate AI into the Digital Pathology WorkflowTribun Health has launched CaloPix Connect, an open API designed to integrate third-party AI solutions into digital pathology workflows through its CaloPix image management system. The API acts as an interoperability layer that enables pathologists to access AI tools—including those from Qritive, Aiforia, DeepPath, Primaa, Owkin, and Ibex—directly within CaloPix without disrupting their existing workflow, while ensuring secure data transfer, GDPR compliance, and standardized integration. Tribun Health aims to position CaloPix as the central platform for AI-augmented pathology, combining case management, slide visualization, and AI integration to drive diagnostic quality and productivity.AETOSWireQritive Secures Multi-Year Contracts with Metropolis Healthcare, CŌRE Diagnostics and Rajiv Gandhi Cancer Institute to Drive AI Adoption in Pathology Across IndiaQritive secured multi-year contracts with Metropolis Healthcare, CŌRE Diagnostics, and Rajiv Gandhi Cancer Institute to integrate its AI pathology platform. The company claims its AI modules enable up to 90% faster diagnoses and 80% less discordance. The partnerships aim to improve diagnostic precision and patient outcomes across India.RocheAI in pathology: Enhancing clinical decision makingHealthcare Transformers interviewed Bruno Occhipinti, CEO of Qritive, on the challenges facing global pathology, including declining pathologist numbers, an aging workforce, and rising cancer case volumes reaching 20 million annually. Qritive's AI-powered solutions demonstrated significant improvements in diagnostic accuracy and speed, including a 90% reduction in metastatic deposit detection time and up to 82% accuracy gains in studies conducted with Singapore General Hospital. The article examines barriers to AI adoption in pathology—including digital infrastructure costs, regulatory inconsistencies across regions, and clinician training needs—while highlighting Qritive's strategic partnership with Roche to expand market access and facilitate clinical adoption through an open ecosystem approach.Business Wire BlogQritive Secures Multi-Year Contracts with Metropolis Healthcare, CŌRE Diagnostics and Rajiv Gandhi Cancer Institute to Drive AI Adoption in Pathology Across IndiaQritive announced multi-year contracts with Metropolis Healthcare, CŌRE Diagnostics, and Rajiv Gandhi Cancer Institute to drive AI adoption in pathology. The partnerships integrate Qritive's Pantheon image management system and AI modules, which claim up to 90% faster diagnoses and 80% less discordance. The collaboration aims to improve diagnostic precision and patient outcomes across India.Business Wire BlogQritive Secures Multi-Year Contracts with Metropolis Healthcare, CŌRE Diagnostics and Rajiv Gandhi Cancer Institute to Drive AI Adoption in Pathology Across IndiaQritive secured multi-year contracts with Metropolis Healthcare, CŌRE Diagnostics, and Rajiv Gandhi Cancer Institute to integrate its AI pathology platform. The company claims its AI delivers up to 90% faster diagnoses and 80% less discordance. The partnerships aim to improve diagnostic precision and patient outcomes across India.BioWorldQritive launches AI-based diagnosis tool for prostate cancerQritive Pte. Ltd. launched Qai Prostate, an AI-powered diagnostic tool, to help pathologists detect prostate cancer. The tool was introduced on April 24, 2023, and is intended to assist in prostate cancer diagnosis.PR Newswire APACQritive and Corista Announce Partnership to Advance the Use of Computational Digital Pathology Workflows with Integrated Image ManagementQritive and Corista announced a partnership integrating Qritive's AI modules with Corista's DP3 image management platform. The combined solution screens for prostate and colon cancers, quantifies IHC markers, and detects lymph node metastasis. It aims to improve pathologist efficiency and support complex case review.PR Newswire APACHealthcare AI Firm Qritive Raises $7.5M to Expand into New MarketsHealthcare AI startup Qritive has raised $7.5 million in a funding round led by MassMutual Ventures, with participation from SEEDS Capital and Exfinity Venture Partners. The company intends to use the capital to drive geographical expansion, broaden its product portfolio, and secure regulatory clearances for its digital pathology solutions.